Omnicell (OMCL) stock soared 12.22% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results and raised full-year guidance. The medication management technology company significantly outperformed analyst expectations, demonstrating robust growth and improved profitability.

For Q2 2025, Omnicell reported revenues of $291 million, up 5% year-over-year and surpassing the consensus estimate of $275.24 million. The company's adjusted earnings per share (EPS) came in at $0.45, substantially beating the expected $0.26. This strong performance was driven by increased demand for connected devices, technical services, SaaS and Expert Services, and consumables revenues.

Adding to investor optimism, Omnicell raised its full-year 2025 guidance for total revenues, non-GAAP EBITDA, and non-GAAP EPS. The company also provided a positive outlook for Q3, projecting revenues between $290 million and $300 million, above the consensus of $284.1 million. Furthermore, Omnicell highlighted its ongoing innovation efforts, including the introduction of new solutions such as the MedTrack RFID Line and MedVision inventory management solution, which are expected to contribute to future growth and maintain the company's leadership position in medication management technology.